MedTrace Logo

Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.

NCT01135186 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-09-10

Study results available
· View outcomes & findings →

Summary

Kuvan® (sapropterin dihydrochloride) for Improving Gastric Accommodation in Women with Diabetic Gastroparesis (KIGA-DG)

Conditions

Interventions

DRUG

sapropterin dihydrochloride

sapropterin dihydrochloride: 10mg/kg/day

Sponsors & Collaborators

Principal Investigators

  • Linda A Nguyen · Stanford University

  • Pankaj Jay Pasricha · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01135186 on ClinicalTrials.gov